The antibody may comprise a chimeric antibody.
The therapeutic antibody can include a human antibody, a humanized antibody, a chimeric antibody, or a functional fragment thereof.
More particularly, the isolated monoclonal antibody is selected from the group consisting of a murine antibody, a chimeric antibody, a humanized antibody, and a human antibody.
In a particular embodiment, said antibody is selected from the group consisting of a murine antibody, a chimeric antibody, a humanized antibody, and a human antibody.
More particularly, the antibodies of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; and a F(ab')2 fragment of BR96.
The recombinant antibody is preferably a humanised antibody and may be a chimeric or CDR-grafted antibody.
A chimeric anti-CEA antibody comparable to ATCC Accession No. BH 8747 is described.
The antibody may be a chimaeric or a humanised (CDR-grafted) antibody for example a humanised antibody against the CDw52 antigen.
The invention relates to a method of producing a chimaeric antibody in which the CDR of a first antibody is spliced between the framework regions of a second antibody.
A murine/human chimeric anti-idiotype monoclonal antibody is provided which has murine complementarity determining regions fused to human constant regions.
Monoclonal antibodies, in particular 33.28 and 31.1, and chimeric antibodies, in particular mouse/human chimeric Chi #1 specific for glycoprotein antigens of colon carcinoma-associated antigens which are immunogenic in humans, are disclosed.
A chimeric anti-FHV-1 recombinant antibody is prepared from the above gene fragment and another gene fragment coding for a feline antibody C region.
It is also found that a chimeric antibody in which the sequence of a constant region is changed to human IgGl/k can induce potent ADCC when used in combination with a human effector cell.
The substitution of an amino acid residue is introduced into a humanized L-chain sequence in the humanized antibody to produce a humanized antibody having the same level of binding activity as that of the chimeric antibody.